Cambiotics has raised EUR 4 million in a seed financing round

Danish biotech startup Cambiotics has raised EUR 4 million in a seed financing round, led by Collaborative Fund with participation from EIFO and True.

Cambiotics develops probiotic supplements designed to help reduce PFAS levels in the human body. PFAS are a large group of chemicals that are widely used and degrade very slowly, making them an increasing concern for global health.

The funding will support the advancement of Cambiotics' scientific and clinical roadmap of its debut product, 46&., including the initiation of its first human clinical trial in the US.

True is a UK-based consumer specialist investment and innovation advisory firm. Their focus will be on bringing consumer sector expertise to help launch and scale Cambiotics’ 46& in major markets globally.

Mazanti Transactions has advised True on their investment.